Well Cell® is a family of companies headed by Well Cell Global LLC, a Research and Development Biotech Healthcare Company with principal offices in Houston, Texas. Well Cell, with three U. S. patents issued and one international patent pending, is the global leader in Glucose Metabolism Optimization as developer and licensor of Physiologic Insulin Resensitization®, referred to as “PIR®.”

PIR is a defined treatment procedure to aid physicians in their care for patients with metabolic diseases such as diabetes by using insulin as a hormone rather than a drug or mere symptom suppressant, with focus on improving increasing insulin sensitivity and reducing insulin resistance having positive implications at the cellular level. The improvements observed by patients, physicians, and other medical professionals include neuropathy, nephropathy, retinopathy, and wound healing. Peer-reviewed published articles may be found at Well Cell’s Website, www.wellcellglobal.com, and we encourage all readers to share them.

PIR method has been in development, study, and clinical trial research since 2015, ever on an upward path, with more than 200 licenses issued for the patented process and university collaborations active worldwide. Guided by its Medical and Scientific Advisory Board, Well Cell’s goal is to become the standard for treatment of metabolic disorder and other diseases that plague humanity in increasing numbers every year. Notable recent improvements in kidney disease experienced by Island Doctors in Florida are gaining increased attention from medical professionals in the USA and abroad. Contact Chief Growth Officer Glenn Massey, 888.991.1012, for information.